Indication

Hepatocellular Carcinoma

Clinical and regulatory intelligence for Hepatocellular Carcinoma with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Assets: 5

Relevant assets

Relevant companies

Alnylam Pharmaceuticals →

AstraZeneca →

Recent signals(5)

ClinicalJune 21, 2026

Dual-ligand cantharidin nanoparticles show promise for hepatocellular carcinoma treatment

Dual-ligand-modified cantharidin nanoparticles demonstrated a 58.67% tumor inhibition rate in Huh-7 tumor-bearing mice, with enhanced safety profiles.

ClinicalJune 21, 2026

Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy

Alnylam Pharmaceuticals is conducting a study to evaluate the safety and antitumor activity of ALN-BCAT, both alone and in combination with pembrolizumab, in patients with hepatocellular carcinoma.

ClinicalJune 20, 2026

High-Intensity Thermal Stress Boosts NK-Cell Cytotoxicity in HCC

High-intensity thermal stress enhances the cytotoxicity of NK-cells in poorly differentiated hepatocellular carcinoma.

ClinicalJune 20, 2026

MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation

MAGED4 is upregulated in hepatocellular carcinoma and promotes tumor progression by activating the JAK2/STAT3 pathway.

ClinicalJune 17, 2026

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Hepatocellular Carcinoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.